Table 1.
Main large samples (> 1000 patients) studies on Bipolar Disorder published in the last ten years
| Authors | Site | Sample | N° of BD patients recruited | Female patients (%) |
|---|---|---|---|---|
| Bareis et al. 2018 | U.S.A. | STEP-BD (1999-2005) | 3563 | 57,65% |
| Bobo et al. 2018 | U.S.A. | Mayo Clinic Biobank (started in 2009) |
1465 BD-I = 69,42% BD-II = 30,58% |
60,75% BD-I = 58,60% BD-II = 66,10% |
| Buoli et al. 2019 | Italy | RENDiBi Study (April 2014-March 2015) |
1675 BD-I = 62,21% BD-II = 37,79% |
57,40% |
| Crump et al. 2013 | Sweden | National Registry (2001-2002) | 6618 | 59,20% |
| Hayes et al. 2017 | U.K. | Primary care electronics health records (THIN) (2000-2014) | 17341 | 58,83% |
| Hou et al. 2016 | Australia, Canada, Czech Republic, France, Germany, Italy, Japan, Poland, Romania,Spain, Sweden, Switzerland, Taiwan, U.S.A. | ConLiGen | 2563 | 57,63% |
| Kalman et al. 2019 | Austria, Australia, Canada, Czech Republic, France, Germany, Italy, Poland, Romania, Spain, Sweden, U.S.A. | ConLiGen, Bonn-Mannheim and PsyCourse | 1995 (BD-I patients only) | 55,10% |
| Karanti et al. 2015 | Sweden | Swedish National Quality Assurance Register for Bipolar Disorder (BipoläR) (2004-2011) |
7136 BD-I = 47,09% BD-II = 38,15% BD-NOS = 14,76% |
61,27% BD-I = 57,30% BD-II = 64,95% BD-NOS = 64,42% |
| Vieta et al. 2013 | Austria, Belgium, Brazil, France, Germany, Portugal, Romania, Turkey, Ukraine, Venezuela | WAVE-BD (April 2010- June 2011) |
2896 BD-I = 68,70% BD-II = 31,3% |
65,00% |
| Yoon et al. 2018 | Korea | Korean HIRA-NPS (2013 sample only) | 2626 | 58,80% |
THIN = The Health Improvement Network; STEP-BD = Systematic Treatment Enhancement Program for Bipolar Disorder; RENDiBi = National Epidemiological Research on Bipolar Disorder; HIRA-NPS = Health Insurance Review and Assessment Service – National Patient Sample; WAVE-BD = Wide Ambispective of Bipolar Disorder; ConLiGen = The International Consortium on Lithium Genetics; BD-I = Bipolar Disorder type I